Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2024-10-24 Earnings Release
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing the unaudited financial results for the second quarter and half year ended September 30, 2024. It includes key financial metrics such as revenue, EBITDA, PAT, cash flow, and operational updates. The document references the quarter and half year period explicitly and provides detailed financial performance highlights, but it is not a full comprehensive financial report like an Annual Report or Interim Report. It is also not a transcript, governance, or management change announcement. The document is a typical earnings release format, providing initial financial results and commentary from management. Therefore, the appropriate classification is Earnings Release (ER). The document length (6269 characters) and content support this classification with high confidence. Q2 2025
2024-10-24 English
General Updates
Share Issue/Capital Change Classification · 95% confidence The document is a formal letter addressed to stock exchanges and regulatory bodies informing about the allotment of equity shares under an Employee Stock Option Scheme. It details the number of shares allotted, the increase in paid-up share capital, and compliance with SEBI regulations. The content focuses on the issuance of new shares and changes in capital structure due to employee stock options. There are no financial statements, earnings data, or management discussion. The document is an announcement of a capital change event rather than a full report or financial statement. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length is about 5410 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is SHA with high confidence.
2024-10-24 English
Financial Result Updates
Regulatory Filings
2024-10-24 English
General Updates
Major Shareholding Notification Classification · 95% confidence The document is a formal notification addressed to stock exchanges (NSE and BSE) regarding the reclassification of certain shareholders from the 'Promoter & Promoter Group' category to the 'Public Shareholders' category. It references Regulation 31A of the SEBI Listing Regulations, which governs such reclassifications. The document includes approval letters from the exchanges confirming the reclassification. There are no financial statements, earnings data, or management discussion and analysis present. The content is a regulatory disclosure about shareholding category changes, which fits the definition of a Major Shareholding Notification (MRQ). The document length is 4718 characters, which is sufficient for a detailed notification but not a full financial report. Therefore, the appropriate classification is MRQ with high confidence.
2024-10-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (NSE and BSE) informing them about an upcoming earnings call scheduled for October 25, 2024. It includes details such as date, time, dial-in numbers, and contact information for clarifications. The document does not contain any financial data, analysis, or results itself, but rather serves as an announcement or invitation to the earnings call event. The document length is 2474 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about the earnings call event, not the earnings release or call transcript itself.
2024-10-18 English
Board Meeting — GLENMARK LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 24-Oct-2024 to inter-alia consider and approve the Audited Financial results of the Company…
Regulatory Filings
2024-10-17 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.